immunocompromised patients Archives

Isavuconazole designated QIDP in the US for the treatment of invasive candidiasis, Basilea seeks additional approval in EU for treatment of invasive mold infections

By Staff

Basilea Pharmaceutica Ltd. reported this week that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the oral and intravenous treatment...